Drug Delivery Systems Market (Delivery System - Intrauterine Implants, Prodrug Implants, Polymeric Drug Delivery, Targeted Drug Delivery; Application - Infectious Diseases, Oncology, Urology, Diabetes, CNS; Route of Administration - Oral, Injectable, Inhalation, Transdermal, Ocular, Nasal, and Topical) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2030

Drug Delivery Systems Market: Snapshot

Drug delivery includes formulations, technologies, methods, and systems for transferring an active pharmaceutical ingredients into the body to safely provide therapeutic effect. The global drug delivery systems market was valued approximately US$ 510 Bn in 2016 and is anticipated to expand at a CAGR of over 6.9% from 2017 to 2025 to reach approximately US$ 900 Bn by 2025. Increase in demand for self-administration and home health care devices are likely to fuel expansion of the global drug delivery systems market from 2017 to 2025.

Continuous innovations in the global drug delivery systems market is creating opportunities for major and local manufacturers to develop wide product portfolio. Additionally, collaborations among major market players for superior technological advancements in drug delivery offerings is likely to drive the global drug delivery systems market during the forecast period. Using nanotechnology, the drug can be targeted to a precise location, which makes drugs more effective and reduce the chances of possible side effects. Major manufacturers operating in the market are involved in continuous research & development activities to expand their already wide product portfolio. For instance, on September 2017, Baxter International Inc. announced the launch of DeviceVue, an asset tracking system for sigma spectrum infusion system whereas, emerging players operating in the market are also focusing on introducing new versions of their existing drug delivery devices. Continuous expansion of drug delivery systems offering in high throughput along with reduced waiting time and improved result specificity are likely to drive the global drug delivery systems during the forecast period. However, high cost associated with treatment and increase in drug recalls are likely to restrain the global drug delivery systems market during the forecast period.

The global drug delivery systems market has been segmented based on delivery system, application, route of administration, and geography. In terms of delivery system, the targeted drug delivery segment is projected to continue its dominance during the forecast period followed by the polymeric drug delivery segment. Introduction of new drug delivery devices such as SmartDose wearable injector and increase in demand for targeted and low dose frequency drug delivery is likely to propel the segment. Based on application, oncology was the leading revenue generating segment in 2016 and it is likely to continue its dominance during the forecast period due to the increase in prevalence of various types of cancer. According to WHO report, in the year 2015, around 70% of cancer-related deaths occurred in low- and middle- income countries. The infectious diseases segment is likely to lose market share during the forecast period owing rise in preference to develop oncology and diabetes drug delivery system by manufactures. In terms of route of administration, injectable dominated the market in 2016 and is likely to account for a leading share during the forecast period.

Geographically, North America accounted for a leading share of the global drug delivery system market in 2016. However, rise in research & development expenses for advanced drug delivery devices in the U.S. is key concern area among key players. The market in Asia Pacific is projected to gain share during the forecast period and is likely to be key revenue generator in the next few years. Initiatives by local governments for self-sufficiency in manufacturing pharmaceuticals and prevalence of various diseases in countries such as Brazil, South Africa, Saudi Arabia, etc. are anticipated to boost market in Latin America and Middle East & Africa.

Key companies operating in the global drug delivery systems market and profiled in the report include AstraZeneca plc., Bayer AG, Pfizer, Inc., Novartis AG, Amgen Inc., Johnson and Johnson Services, Inc., Baxter International, Inc., Boston Scientific Corporation, and Becton, Dickinson & Company. These players adopt organic and in-organic growth strategies to expand their product offerings, strengthen their geographical reach, increase customer base, and garner market share. For instance, in June 30, 2017, the F. Hoffmann-La Roche Ltd. acquired mySugr, a company that is dedicated to developing applications and software for diabetes care.

The global drug delivery systems market has been segmented as follows:

by Type of Delivery System

• Intrauterine Implants
• Prodrug Implants
• Polymeric Drug Delivery
• Targeted Drug Delivery

 by Application

• Infectious Diseases
• Oncology
• Ophthalmology
• Urology
• Diabetes
• CNS
• Others

by Route of Administration

• Oral
• Injectable
• Inhalation
• Ocular
• Nasal
• Topical

by Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Australia & New Zealand
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• GCC Countries
• South Africa
• Israel
• Rest of MEA

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Drug Delivery Systems Market

Chapter 4. Market Overview
4.1. Introduction
       4.1.1. Product Overview
       4.1.2. Industry Evolution / Developments
4.2. Market Dynamics 
       4.2.1. Drivers
       4.2.2. Restraints
       4.2.3. Opportunities
4.3. Pipeline Analysis - Drug Therapy Products 
4.4. Porter’s Five Force Analysis
4.5. Technological Advancement in Drug Delivery Products 
4.6. Regulatory Scenario
4.7. Key Mergers and Acquisitions
4.8. Global Drug Delivery Systems Market Analysis and Forecasts, 2015–2025
       4.8.1. Market Revenue Projection (US$ Mn)
       4.8.2. Market Outlook

Chapter 5. Global Drug Delivery Systems Market Analysis and Forecasts, by Type of Delivery System
5.1. Key Findings / Developments
5.2. Introduction & Definition
5.3. Market Value Forecast by Delivery Systems, 2016–2025
       5.3.1. Intrauterine Implants
       5.3.2. Prodrug Implants
       5.3.3. Polymeric Drug Delivery
       5.3.4. Targeted Drug Delivery
5.4. Market Attractiveness by Delivery Systems

Chapter 6. Global Drug Delivery Systems Market Analysis and Forecasts, by Application
6.1. Key Findings / Developments
6.2. Introduction & Definition
6.3. Market Value and Volume Forecast by Application, 2016–2025
       6.3.1. Infectious Diseases
       6.3.2. Oncology
       6.3.3. Ophthalmology
       6.3.4. Urology
       6.3.5. Diabetes
       6.3.6. CNS
       6.3.7. Others
6.4. Market Attractiveness by Application

Chapter 7. Global Drug Delivery Systems Market Analysis and Forecasts, by Route of Administration
7.1. Key Findings / Developments
7.2. Introduction & Definition
7.3. Market Value and Volume Forecast by Route of Administration, 2016–2025
       7.3.1. Oral
       7.3.2. Injectable
       7.3.3. Inhalation
       7.3.4. Transdermal
       7.3.5. Ocular
       7.3.6. Nasal
       7.3.7. Topical
7.4. Market Attractiveness by Route of Administration

Chapter 8. Global Drug Delivery Systems Market Analysis and Forecasts, by Geography / Region 
8.1. Geographical Representation
8.2. Market Value and Volume Forecast by Region
       8.2.1. North America 
       8.2.2. Europe 
       8.2.3. Asia Pacific 
       8.2.4. Latin America 
       8.2.5. Middle  East & Africa 
8.3. Market Attractiveness by Region

Chapter 9. North America Drug Delivery Systems Market Analysis and Forecast 
9.1. Market Value Forecast by Country, 2017–2025
       9.1.1. U.S.
       9.1.2. Canada
9.2. Market Value Forecast by Type of Delivery System, 2016–2025
9.3. Market Value Forecast by Application, 2016–2025
9.4. Market Value Forecast by Route of Administration, 2016–2025
9.5. Market Attractiveness Analysis
       9.5.1. by Country
       9.5.2. by Type of Delivery System
       9.5.3. by Application
       9.5.4. by Route of Administration

Chapter 10. Europe Drug Delivery Systems Market Analysis and Forecast 
10.1. Market Value Forecast by Country, 2017–2025
       10.1.1. Germany
       10.1.2. France
       10.1.3. U.K.
       10.1.4. Spain
       10.1.5. Italy
       10.1.6. Rest of Europe
10.2. Market Value Forecast by Type of Delivery System, 2016–2025
10.3. Market Value Forecast by Application, 2016–2025
10.4. Market Value Forecast by Route of Administration, 2016–2025
10.5. Market Attractiveness Analysis
       10.5.1. by Country
       10.5.2. by Type of Delivery System
       10.5.3. by Application
       10.5.4. by Route of Administration

Chapter 11. Asia Pacific Drug Delivery Systems Market Analysis and Forecast 
11.1. Market Value Forecast by Country, 2017–2025
       11.1.1. China
       11.1.2. Japan
       11.1.3. India
       11.1.4. Australia & New Zealand
       11.1.5. Rest of APAC
11.2. Market Value Forecast by Type of Delivery System, 2016–2025
11.3. Market Value Forecast by Application, 2016–2025
11.4. Market Value Forecast by Route of Administration, 2016–2025
11.5. Market Attractiveness Analysis
       11.5.1. by Country
       11.5.2. by Delivery Systems
       11.5.3. by Application
       11.5.4. by Route of Administration

Chapter 12. Latin America Drug Delivery Systems Market Analysis and Forecast 
12.1. Market Value Forecast by Country, 2017–2025
       12.1.1. Brazil
       12.1.2. Mexico
       12.1.3. Rest of LATAM
12.2. Market Value Forecast by Type of Delivery System, 2016–2025
12.3. Market Value Forecast by Application, 2016–2025
12.4. Market Value Forecast by Route of Administration, 2016–2025
12.5. Market Attractiveness Analysis
       12.5.1. by Country
       12.5.2. by Delivery Systems
       12.5.3. by Application
       12.5.4. by Route of Administration

Chapter 13. Middle East and Africa Drug Delivery Systems Market Analysis and Forecast 
13.1. Market Value Forecast by Country, 2017–2025
       13.1.1. GCC Countries
       13.1.2. South Africa
       13.1.3. Israel
       13.1.4. Rest of MEA
13.2. Market Value Forecast by Type of Delivery System, 2016–2025
13.3. Market Value Forecast by Application, 2016–2025
13.4. Market Value Forecast by Route of Administration, 2016–2025
13.5. Market Attractiveness Analysis
       13.5.1. by Country
       13.5.2. by Delivery Systems
       13.5.3. by Application
       13.5.4. by Route of Administration

Chapter 14. Competition Landscape
14.1. Competition Matrix
       14.1.1. Novartis AG
       14.1.2. Amgen Inc.
       14.1.3. F. Hoffmann-La Roche Ltd.
       14.1.4. Pfizer Inc.
14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
       14.2.1. Novartis AG (HQ, Business Segments, Employee Strength)
                 14.2.1.1. Company Details
                 14.2.1.2. Company Description
                 14.2.1.3. Business Overview
                 14.2.1.4. SWOT Analysis
                 14.2.1.5. Financial Analysis
                 14.2.1.6. Strategic Overview
       14.2.2. Amgen Inc. (HQ, Business Segments, Employee Strength)
                 14.2.2.1. Company Details
                 14.2.2.2. Company Description
                 14.2.2.3. Business Overview
                 14.2.2.4. SWOT Analysis
                 14.2.2.5. Strategic Overview
       14.2.3. F.Hoffmann-La Roche Ltd. (HQ, Business Segments, Employee Strength)
                 14.2.3.1. Company Details
                 14.2.3.2. Company Description
                 14.2.3.3. Business Overview
                 14.2.3.4. SWOT Analysis
                 14.2.3.5. Strategic Overview
       14.2.4. Pfizer Inc. (HQ, Business Segments, Employee Strength)
                 14.2.4.1. Company Details
                 14.2.4.2. Company Description
                 14.2.4.3. Business Overview
                 14.2.4.4. SWOT Analysis
                 14.2.4.5. Strategic Overview
       14.2.5. Johnson & Johnson Services, ltd. (HQ, Business Segments, Employee Strength)
                 14.2.5.1. Company Details
                 14.2.5.2. Company Description
                 14.2.5.3. Business Overview
                 14.2.5.4. SWOT Analysis
                 14.2.5.5. Financial Analysis
                 14.2.5.6. Strategic Overview
       14.2.6. Becton, Dickinson and Company (HQ, Business Segments, Employee Strength)
                 14.2.6.1. Company Details
                 14.2.6.2. Company Description
                 14.2.6.3. Business Overview
                 14.2.6.4. SWOT Analysis
                 14.2.6.5. Financial Analysis
                 14.2.6.6. Strategic Overview
       14.2.7. AstraZeneca plc (HQ, Business Segments, Employee Strength)
                 14.2.7.1. Company Details
                 14.2.7.2. Company Description
                 14.2.7.3. Business Overview
                 14.2.7.4. SWOT Analysis
                 14.2.7.5. Financial Analysis
                 14.2.7.6. Strategic Overview
       14.2.8. Baxter International, Inc. (HQ, Business Segments, Employee Strength)
                 14.2.8.1. Company Details
                 14.2.8.2. Company Description
                 14.2.8.3. Business Overview
                 14.2.8.4. SWOT Analysis
                 14.2.8.5. Financial Analysis
                 14.2.8.6. Strategic Overview
       14.2.9. Bayer AG (HQ, Business Segments, Employee Strength)
                 14.2.9.1. Company Details
                 14.2.9.2. Company Description
                 14.2.9.3. Business Overview
                 14.2.9.4. SWOT Analysis
                 14.2.9.5. Strategic Overview
       14.2.10. Boston Scientific Corporation (HQ, Business Segments, Employee Strength)
                 14.2.10.1. Company Details
                 14.2.10.2. Company Description
                 14.2.10.3. Business Overview
                 14.2.10.4. SWOT Analysis
                 14.2.10.5. Strategic Overview